FGFR1 and non-small cell lung carcinoma: Similar findings were observed for amplifications, which are rare for FGFR3 and FGFR4, while FGFR1 amplification was found in up to 19% of NSCLC and hormone-receptor-positive breast cancer (dropping to 4% in triple-negative breast cancer) [42,43,44,45].